Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy

Mark H Rozenbaum, Diana Tran, Rahul Bhambri, Jose Nativi-Nicolau, Mark H Rozenbaum, Diana Tran, Rahul Bhambri, Jose Nativi-Nicolau

Abstract

Background: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) experience infiltrative cardiomyopathy and heart failure symptoms requiring costly hospitalizations. The Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT) demonstrated the efficacy of tafamidis on the frequency of cardiovascular (CV)-related hospitalizations in patients with ATTR-CM.

Purpose: As length of stay can affect the total hospitalization burden, our study aimed to better understand the impact of tafamidis on the number of CV-related hospital days avoided in the management of ATTR-CM patients.

Methods: Data from ATTR-ACT were used to calculate the total burden of CV-related hospitalization (days) by treatment arm in this post hoc analysis.

Results: In the total trial population, patients receiving tafamidis had significantly fewer CV-related hospitalizations per year (relative risk reduction [RRR] 0.68; 0.4750 vs. 0.7025, p < 0.0001) and a shorter mean length of stay per CV-related hospitalization event (8.6250 vs. 9.5625 days) than patients receiving placebo. Taken together, tafamidis prevented 2.62 CV-related hospitalization days per patient per year. A subgroup analysis showed that with earlier treatment initiation of tafamidis, the annual number of CV-related hospitalizations was significantly lowered by 52% compared with placebo (RRR 0.48; 0.3378 vs. 0.7091, p < 0.0001). With 1.14 fewer days per hospitalization, tafamidis reduced the annual number of CV-related hospitalization days by 3.96 days per New York Heart Association class I/II patient.

Conclusions: In patients with ATTR-CM, tafamidis was associated with a lower rate of CV-related hospitalizations and shorter length of hospital stay. Timely diagnosis and treatment with tafamidis could further decrease the total number of CV-related hospitalization days per year.

Gov identifier: NCT01994889.

Conflict of interest statement

Mark Rozenbaum and Rahul Bhambri are employees of Pfizer and hold Pfizer stock and/or stock options. Editorial/medical writing support and data analysis were provided by Diana Tran at EVERSANA and was funded by Pfizer Inc. Jose Nativi-Nicolau received funding for clinical trials from Pfizer, Akcea, and Eidos and Educational Grants from Pfizer and has been a consultant for Pfizer, Eidos, Akcea, and Alnylam.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Tafamidis is associated with lower total mean CV-related hospitalization days compared with placebo in the total population and baseline NYHA class I/II subpopulation. CV cardiovascular, NYHA New York Heart Association Functional Classification

References

    1. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872–2891. doi: 10.1016/j.jacc.2019.04.003.
    1. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806. doi: 10.1093/eurheartj/ehx589.
    1. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–1020. doi: 10.1016/j.jacc.2016.06.033.
    1. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098. doi: 10.1161/JAHA.113.000098.
    1. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS) Am Heart J. 2012;164(2):222–8 e1. doi: 10.1016/j.ahj.2012.04.015.
    1. Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2021. 10.1007/s10741-021-10080-2.
    1. Jackson SL, Tong X, King RJ, Loustalot F, Hong Y, Ritchey MD. National burden of heart failure events in the United States, 2006 to 2014. Circ Heart Fail. 2018;11(12):e004873. doi: 10.1161/CIRCHEARTFAILURE.117.004873.
    1. Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, et al. A systematic review of medical costs associated with heart failure in the USA (2014–2020) Pharmacoeconomics. 2020;38(11):1219–1236. doi: 10.1007/s40273-020-00952-0.
    1. Llonch MV, Ortiz-Perez JT, Reddy SR, Chang E, Tarbox MH, Pollock MR, et al. Cardiovascular disease burden prior to hereditary transthyretin amyloidosis diagnosis. J Card Fail. 2020;26(10):S125–S126. doi: 10.1016/j.cardfail.2020.09.362.
    1. Sperry BW, Saeed IM, Raza S, Kennedy KF, Hanna M, Spertus JA. Increasing rate of hospital admissions in patients with amyloidosis (from the national inpatient sample) Am J Cardiol. 2019;124(11):1765–1769. doi: 10.1016/j.amjcard.2019.08.045.
    1. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi: 10.1056/NEJMoa1805689.
    1. Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis—a clinical challenge. Int J Cardiol. 2020;1(304):138–143. doi: 10.1016/j.ijcard.2019.12.063.
    1. Rozenbaum MH, Large S, Bhambri R, Stewart M, Young R, Doornewaard AV, et al. Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy. J Comp Eff Res. 2021;10(11):927–938. doi: 10.2217/cer-2021-0071.
    1. Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther. 2021;10(1):141–159. doi: 10.1007/s40119-021-00219-5.
    1. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7–e22. doi: 10.1161/CIR.0000000000000792.
    1. Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, et al. Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey. JACC CardioOncol. 2021;3(4):537–546. doi: 10.1016/j.jaccao.2021.08.009.
    1. Rozenbaum MH, Ionescu I, Clausen M, Lopez M, Sultan MB, Attal S. Baseline characteristics of patients with transthyretin amyloid cardiomyopathy enrolled in a tafamidis expanded access program. Eur Heart J. 2021;42(Supplement_1):ehab724.1799
    1. Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail. 2021;9(2):115–123. doi: 10.1016/j.jchf.2020.09.011.
    1. Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, et al. Design and rationale of the phase 3 ATTR-ACT clinical trial (tafamidis in transthyretin cardiomyopathy clinical trial) Circ Heart Fail. 2017;10(6):e003815. doi: 10.1161/CIRCHEARTFAILURE.116.003815.
    1. Vong C, Boucher M, Riley S, Harnisch LO. Modeling of survival and frequency of cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. Am J Cardiovasc Drugs. 2021;21(5):535–543. doi: 10.1007/s40256-021-00464-y.
    1. Li H, Rozenbaum MH, Casey M, Sultan MB. Estimating treatment effect of tafamidis on hospitalization in NYHA class III ATTR-CM patients in the presence of death using principal stratification. Eur Heart J. 2021;42(Supplement_1):ehab724.0829.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다